# StrateGIST 3 (NCT07218926)

> A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07218926
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Gastrointestinal Neoplasms
- Interventions: IDRX-42; Sunitinib
- Enrollment: 450
- Primary outcome: Progression-Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- Podcasts: 2
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=strategist-3-nct07218926

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07218926", "email": "<work email>"}; the inbox owner confirms by the emailed link.